.gamma.-brain natriuretic peptide
Also known as: BNP C-terminal fragment, gamma-BNP, N-terminal pro-BNP fragment, proBNP, γ-BNP
Source .gamma.-brain natriuretic peptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
γ‑Brain natriuretic peptide (γ‑BNP) is the high‑molecular‑weight, 106‑amino‑acid precursor of the cardiac hormone brain natriuretic peptide. It contains the C‑terminal BNP‑32 sequence and is stored in cardiac atrium and other tissues such as the adrenal gland. In normal plasma the γ‑form is the predominant circulating species, whereas BNP‑32 dominates in heart tissue. Plasma γ‑BNP rises markedly in heart disease and experimental hypertension, indicating its role as a marker of cardiac BNP synthesis and storage.
Mechanism of Action
γ‑BNP functions as a pro‑hormone that is proteolytically cleaved to release the active 32‑amino‑acid BNP peptide. The released BNP‑32 binds natriuretic peptide receptors, stimulating intracellular cGMP production, which promotes natriuresis, vasodilation and inhibition of the renin‑angiotensin system. Thus γ‑BNP serves as a storage and transport form that can be mobilised when the heart needs to regulate blood pressure and fluid balance.
What the Research Shows
The γ‑form of BNP was first isolated from porcine cardiac atrium and shown to contain a C‑terminal BNP structure (Minamino et al., 1988). In human heart tissue, including transplanted ventricles, γ‑BNP accounts for about 20 % of total immunoreactive BNP, while the α‑form is dominant (Ationu & Carter, 1994). γ‑BNP is also present in normal adrenal glands and adrenal tumors, where multiple molecular forms coexist (Totsune et al., 1996). In plasma of healthy young men, γ‑BNP is the main circulating form, whereas BNP‑32 predominates in cardiac atrium (Tateyama et al., 1992). In a DOCA‑salt rat model of hypertension, plasma γ‑BNP levels correlate with blood pressure and show tissue‑specific shifts, suggesting a role in pressure regulation (Yokota et al., 1990). Overall, studies across species describe γ‑BNP as a storage precursor whose levels reflect cardiac BNP production.
Reported Benefits
Evidence from human plasma and tissue studies indicates that γ‑BNP levels rise in heart disease and correlate with blood pressure in animal models, suggesting it may serve as a biomarker of cardiac stress and BNP synthesis. Its presence in adrenal tissue also points to broader endocrine relevance. However, the utility of γ‑BNP as a diagnostic or prognostic marker remains preliminary, based on limited cohort sizes.
Limitations of the Evidence
Research on γ‑BNP is confined to observational measurements in small human samples and animal experiments; no interventional or longitudinal clinical trials exist. The functional significance of the γ‑form versus the active BNP‑32 peptide is not established, and assays often detect both forms together, complicating interpretation. Consequently, conclusions about its physiological role or clinical value are tentative.
Safety Considerations
γ‑BNP is a research‑grade peptide with no approved therapeutic indication. No safety, toxicity, or adverse‑event data have been reported in the literature. Use is limited to laboratory measurement or experimental studies; human administration has not been evaluated.
How It Is Administered
In research settings γ‑BNP is typically measured in plasma or tissue extracts using radioimmunoassay or high‑performance liquid chromatography. No formulation for clinical administration exists, and routes of delivery have not been described.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- volume status assessmentDiagnosticLow
- Biomarker research for heart failureResearch/DiagnosticLow
- Understanding BNP metabolismResearchModerate
- cardiovascular risk stratificationPrognosticLow
- heart failure diagnosisDiagnosticModerate
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
- European UnionUnapprovedNo therapeutic approval
- United StatesUnapprovedNo therapeutic approval; biomarker use only under CLIA
- United KingdomUnknownNo established regulatory framework
Not approved as therapeutic agent; used as biomarker in cardiovascular diagnostics
Evidence & Sources
- Journal ArticleLowMinamino N, Kangawa K, Matsuo H1988-01-01T00:00:00.000000Z
- Journal ArticleLowAtionu A, Carter ND1994-01-01T00:00:00.000000Z
- Journal ArticleLowTotsune K, et al.1996-01-01T00:00:00.000000Z
- Journal ArticleLowYokota N, et al.1990-01-01T00:00:00.000000Z
- Journal ArticleLowTateyama H, et al.1992-01-01T00:00:00.000000Z
- Journal ArticleLowAburaya M, et al.1989-01-01T00:00:00.000000Z
Frequently Asked Questions
What is the difference between γ‑BNP and the active BNP‑32 peptide?
γ‑BNP is a larger, 106‑amino‑acid precursor that stores the C‑terminal BNP‑32 sequence. Proteolytic processing cleaves γ‑BNP to release the shorter BNP‑32, which is the biologically active hormone that binds natriuretic peptide receptors.
Can γ‑BNP be used to diagnose heart failure?
Current evidence shows γ‑BNP levels rise in heart disease, but studies are small and assays often detect both γ‑BNP and BNP‑32 together. Therefore γ‑BNP alone is not an established diagnostic marker for heart failure.
Is γ‑BNP approved for any therapeutic use?
No. γ‑BNP is classified as a research compound; it has not been evaluated for safety or efficacy in humans and holds no regulatory approval for treatment.
How is γ‑BNP measured in the laboratory?
Researchers use high‑sensitivity radioimmunoassays and chromatographic techniques (e.g., HPLC) to detect and differentiate γ‑BNP from other BNP forms in plasma or tissue samples.
Does γ‑BNP have a role outside the heart?
Immunoreactive γ‑BNP has been identified in normal adrenal glands and adrenal tumors, indicating it may be produced in other endocrine tissues, though its functional significance there remains unclear.
What is .gamma.-brain natriuretic peptide used for?
.gamma.-brain natriuretic peptide is educationally associated with: volume status assessment, Biomarker research for heart failure, Understanding BNP metabolism, cardiovascular risk stratification, heart failure diagnosis. Educational only — not medical advice.